WallStSmart

Cardinal Health Inc (CAH)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cardinal Health Inc generates 1952% more annual revenue ($250.74B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 0.6%. CAH appears more attractively valued with a PEG of 1.25. VRTX earns a higher WallStSmart Score of 66/100 (B-).

CAH

Hold

47

out of 100

Grade: D+

Growth: 4.7Profit: 4.5Value: 7.3Quality: 5.8
Piotroski: 4/9Altman Z: 4.30

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CAHUndervalued (+73.9%)

Margin of Safety

+73.9%

Fair Value

$859.62

Current Price

$183.65

$675.97 discount

UndervaluedFair: $859.62Overvalued
VRTXUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$989.67

Current Price

$429.82

$559.85 discount

UndervaluedFair: $989.67Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CAH2 strengths · Avg: 9.0/10
Altman Z-ScoreHealth
4.3010/10

Safe zone — low bankruptcy risk

Free Cash FlowQuality
$1.68B8/10

Generating 1.7B in free cash flow

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

CAH4 concerns · Avg: 3.3/10
P/E RatioValuation
28.2x4/10

Moderate valuation

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Profit MarginProfitability
0.6%3/10

0.6% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CAH

The strongest argument for CAH centers on Altman Z-Score, Free Cash Flow. Revenue growth of 11.0% demonstrates continued momentum. PEG of 1.25 suggests the stock is reasonably priced for its growth.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : CAH

The primary concerns for CAH are P/E Ratio, Return on Equity, Profit Margin. Thin 0.6% margins leave little buffer for downturns.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

CAH profiles as a value stock while VRTX is a mature play — different risk/reward profiles.

CAH carries more volatility with a beta of 0.54 — expect wider price swings.

CAH is growing revenue faster at 11.0% — sustainability is the question.

CAH generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 47/100), backed by strong 35.5% margins. CAH offers better value entry with a 73.9% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardinal Health Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Cardinal Health, Inc. is an American multinational health care services company.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?